CRISPR Therapeutics AG – NASDAQ:CRSP
CRISPR Therapeutics AG stock price today
$53.954
+13.93
+34.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 2 hours
CRISPR Therapeutics AG stock price monthly change
-30.88%
month
CRISPR Therapeutics AG stock price quarterly change
-30.88%
quarter
CRISPR Therapeutics AG stock price yearly change
-38.39%
year
CRISPR Therapeutics AG key metrics
Market Cap | 3.39B |
Enterprise value | 3.58B |
P/E | -5.36 |
EV/Sales | 8232.56 |
EV/EBITDA | -5.73 |
Price/Sales | 8158.85 |
Price/Book | 1.89 |
PEG ratio | 0.01 |
EPS | -2.69 |
Revenue | N/A |
EBITDA | -283.94M |
Income | -217.13M |
Revenue Q/Q | -99.49% |
Revenue Y/Y | 169.80% |
Profit margin | -149122.71% |
Oper. margin | -154394.72% |
Gross margin | -25186.7% |
EBIT margin | -154394.72% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCRISPR Therapeutics AG stock price history
CRISPR Therapeutics AG stock forecast
CRISPR Therapeutics AG financial statements
Average Price Target
$81
Potential upside: 50.12%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 70M | -77.74M | -111.06% |
|---|---|---|---|
| Sep 2023 | 0 | -112.15M | |
| Dec 2023 | 200M | 89.34M | 44.67% |
| Mar 2024 | 504K | -116.59M | -23133.13% |
| 2022-11-01 | -2.29 | -2.24 |
|---|---|---|
| 2023-02-21 | -0.86475 | -1.41 |
| Jun 2023 | 2197014000 | 380.98M | 17.34% |
|---|---|---|---|
| Sep 2023 | 2086830000 | 359.03M | 17.2% |
| Dec 2023 | 2229571000 | 346.76M | 15.55% |
| Mar 2024 | 2439017000 | 355.08M | 14.56% |
| Jun 2023 | -133.24M | 216.92M | 16.76M |
|---|---|---|---|
| Sep 2023 | -39.85M | 121.34M | 1.55M |
| Dec 2023 | -96.07M | -81.45M | 38.93M |
| Mar 2024 | 109.75M | -97.8M | 305.93M |
CRISPR Therapeutics AG alternative data
Gene editing
| 11 Jun 2023 | 10 |
|---|---|
| 18 Jun 2023 | 12 |
| 25 Jun 2023 | 14 |
| 2 Jul 2023 | 16 |
| 9 Jul 2023 | 18 |
| 16 Jul 2023 | 17 |
| 23 Jul 2023 | 16 |
| 30 Jul 2023 | 28 |
| 6 Aug 2023 | 22 |
| 13 Aug 2023 | 17 |
| 20 Aug 2023 | 18 |
| 27 Aug 2023 | 15 |
| 3 Sep 2023 | 18 |
| 10 Sep 2023 | 21 |
| 17 Sep 2023 | 21 |
| 24 Sep 2023 | 22 |
| 1 Oct 2023 | 25 |
| 8 Oct 2023 | 19 |
| 15 Oct 2023 | 17 |
| 22 Oct 2023 | 17 |
Gene-editing companies
| 26 Feb 2023 | 4 | 19 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| 5 Mar 2023 | 1 | 21 | 0 | 0 | 0 |
| 12 Mar 2023 | 6 | 19 | 0 | 0 | 0 |
| 19 Mar 2023 | 4 | 19 | 0 | 0 | 0 |
| 26 Mar 2023 | 5 | 17 | 0 | 0 | 0 |
| 2 Apr 2023 | 3 | 15 | 0 | 0 | 0 |
| 9 Apr 2023 | 3 | 16 | 0 | 0 | 0 |
| 16 Apr 2023 | 8 | 37 | 0 | 0 | 0 |
| 23 Apr 2023 | 5 | 25 | 0 | 0 | 0 |
| 30 Apr 2023 | 6 | 27 | 0 | 0 | 0 |
| 7 May 2023 | 4 | 22 | 0 | 0 | 0 |
| 14 May 2023 | 6 | 17 | 0 | 0 | 0 |
| 21 May 2023 | 6 | 17 | 0 | 0 | 0 |
| 28 May 2023 | 8 | 17 | 0 | 0 | 0 |
| 4 Jun 2023 | 6 | 25 | 0 | 0 | 0 |
| 11 Jun 2023 | 9 | 36 | 0 | 0 | 0 |
| 18 Jun 2023 | 12 | 48 | 0 | 0 | 0 |
| 25 Jun 2023 | 9 | 42 | 0 | 0 | 0 |
| 2 Jul 2023 | 18 | 67 | 0 | 0 | 0 |
| 9 Jul 2023 | 15 | 65 | 0 | 0 | 0 |
Types of gene editing
| 21 May 2023 | 1 | 9 | 19 |
|---|---|---|---|
| 28 May 2023 | 0 | 9 | 21 |
| 4 Jun 2023 | 1 | 9 | 22 |
| 11 Jun 2023 | 0 | 20 | 31 |
| 18 Jun 2023 | 1 | 16 | 24 |
| 25 Jun 2023 | 1 | 13 | 22 |
| 2 Jul 2023 | 0 | 11 | 21 |
| 9 Jul 2023 | 0 | 10 | 58 |
| 16 Jul 2023 | 0 | 13 | 37 |
| 23 Jul 2023 | 1 | 9 | 29 |
| 30 Jul 2023 | 1 | 9 | 28 |
| 6 Aug 2023 | 0 | 10 | 23 |
| 13 Aug 2023 | 1 | 10 | 29 |
| 20 Aug 2023 | 1 | 10 | 29 |
| 27 Aug 2023 | 1 | 11 | 28 |
| 3 Sep 2023 | 1 | 9 | 34 |
| 10 Sep 2023 | 0 | 19 | 38 |
| 17 Sep 2023 | 1 | 100 | 33 |
| 24 Sep 2023 | 0 | 19 | 31 |
| 1 Oct 2023 | 0 | 13 | 33 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 16 |
|---|---|
| Oct 2023 | 11 |
| Nov 2023 | 8 |
| Dec 2023 | 2 |
| Jan 2024 | 8 |
| Feb 2024 | 7 |
| Apr 2024 | 20 |
| May 2024 | 16 |
| Jun 2024 | 19 |
| Jul 2024 | 12 |
| Sep 2023 | 458 |
|---|---|
| Oct 2023 | 458 |
| Nov 2023 | 458 |
| Dec 2023 | 458 |
| Jan 2024 | 458 |
| Feb 2024 | 458 |
| Mar 2024 | 407 |
| Apr 2024 | 407 |
| May 2024 | 407 |
| Jun 2024 | 407 |
| Jul 2024 | 407 |
CRISPR Therapeutics AG other data
62.72%
+6.56%
of CRSP is owned by hedge funds
418
-16
50.41M
+7.57M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 70000 |
| Feb 2024 | 0 | 28283 |
| Mar 2024 | 0 | 41856 |
| Apr 2024 | 0 | 19582 |
| Jun 2024 | 0 | 3366 |
| Oct 2024 | 0 | 5382 |
| Nov 2024 | 0 | 30000 |
| Dec 2024 | 0 | 15000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KULKARNI SAMARTH director, officer.. | Common Shares | 13,751 | $16.21 | $222,904 | ||
Option | KULKARNI SAMARTH director, officer.. | Stock Option (Right to Buy) | 13,751 | $16.21 | $222,904 | ||
Sale | KULKARNI SAMARTH director, officer.. | Common Shares | 15,000 | $55.1 | $826,560 | ||
Sale | KULKARNI SAMARTH director, officer.. | Common Shares | 23,121 | $55.43 | $1,281,597 | ||
Sale | KULKARNI SAMARTH director, officer.. | Common Shares | 6,879 | $56.27 | $387,081 | ||
Sale | KASINGER JAMES R. officer: General .. | Common Shares | 1,089 | $46.28 | $50,399 | ||
Sale | KULKARNI SAMARTH director, officer.. | Common Shares | 4,293 | $46.28 | $198,680 | ||
Option | KASINGER JAMES R. officer: General .. | Common Shares | 2,113 | N/A | N/A | ||
Option | KASINGER JAMES R. officer: General .. | Restricted Stock Units | 2,113 | N/A | N/A | ||
Option | KULKARNI SAMARTH director, officer.. | Common Shares | 8,333 | N/A | N/A |
| Patent |
|---|
Grant Utility: Universal donor cells Filling date: 23 Jul 2021 Issue date: 6 Sep 2022 |
Grant Utility: Universal donor cells Filling date: 23 Jul 2021 Issue date: 6 Sep 2022 |
Application Filling date: 30 Apr 2020 Issue date: 11 Aug 2022 |
Grant Utility: Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders Filling date: 21 Feb 2018 Issue date: 9 Aug 2022 |
Application Filling date: 7 Nov 2019 Issue date: 21 Jul 2022 |
Grant Utility: Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 Filling date: 22 Apr 2021 Issue date: 19 Jul 2022 |
Application Filling date: 31 Dec 2021 Issue date: 14 Jul 2022 |
Application Filling date: 30 Nov 2021 Issue date: 30 Jun 2022 |
Application Filling date: 22 Dec 2021 Issue date: 23 Jun 2022 |
Application Filling date: 30 Nov 2021 Issue date: 2 Jun 2022 |
| Insider | Compensation |
|---|---|
| Dr. Samarth Kulkarni (1979) Chief Executive Officer & Director | $1,180,000 |
Mr. Michael John Tomsicek M.B.A (1966) Advisor | $678,160 |
| Dr. Lawrence Otto Klein Ph.D. (1982) Chief Operating Officer | $675,000 |
| Mr. James R. Kasinger (1972) Gen. Counsel & Sec. | $648,930 |
CRISPR Therapeutics: Shares Are Soaring--This Could Be The Start Of Something Big
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More
Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
Crispr Therapeutics: Betting On A One-Shot Future
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Undercovered Dozen: Virgin Galactic, Gold Fields, Matador Resources, EHang +
-
What's the price of CRISPR Therapeutics AG stock today?
One share of CRISPR Therapeutics AG stock can currently be purchased for approximately $53.95.
-
When is CRISPR Therapeutics AG's next earnings date?
Unfortunately, CRISPR Therapeutics AG's (CRSP) next earnings date is currently unknown.
-
Does CRISPR Therapeutics AG pay dividends?
No, CRISPR Therapeutics AG does not pay dividends.
-
How much money does CRISPR Therapeutics AG make?
CRISPR Therapeutics AG has a market capitalization of 3.39B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 85038.99% to 371.21M US dollars. CRISPR Therapeutics AG made a loss 153.61M US dollars in net income (profit) last year or -$1.41 on an earnings per share basis.
-
What is CRISPR Therapeutics AG's stock symbol?
CRISPR Therapeutics AG is traded on the NASDAQ under the ticker symbol "CRSP".
-
What is CRISPR Therapeutics AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CRISPR Therapeutics AG?
Shares of CRISPR Therapeutics AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CRISPR Therapeutics AG's key executives?
CRISPR Therapeutics AG's management team includes the following people:
- Dr. Samarth Kulkarni Chief Executive Officer & Director(age: 46, pay: $1,180,000)
- Mr. Michael John Tomsicek M.B.A Advisor(age: 59, pay: $678,160)
- Dr. Lawrence Otto Klein Ph.D. Chief Operating Officer(age: 43, pay: $675,000)
- Mr. James R. Kasinger Gen. Counsel & Sec.(age: 53, pay: $648,930)
-
How many employees does CRISPR Therapeutics AG have?
As Jul 2024, CRISPR Therapeutics AG employs 407 workers.
-
When CRISPR Therapeutics AG went public?
CRISPR Therapeutics AG is publicly traded company for more then 8 years since IPO on 19 Oct 2016.
-
What is CRISPR Therapeutics AG's official website?
The official website for CRISPR Therapeutics AG is crisprtx.com.
-
How can i contact CRISPR Therapeutics AG?
CRISPR Therapeutics AG can be reached via phone at +41 41 561 32 77.
-
What is CRISPR Therapeutics AG stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for CRISPR Therapeutics AG in the last 12 months, the avarage price target is $81. The average price target represents a 50.12% change from the last price of $53.95.
CRISPR Therapeutics AG company profile:
CRISPR Therapeutics AG
crisprtx.comExchange:
NASDAQ
Full time employees:
407
Industry:
Biotechnology
Sector:
Healthcare
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Baarerstrasse 14
Zug, 6300
Zug, 6300
CIK: 0001674416
ISIN: CH0334081137
CUSIP: H17182108
